Valuation: Antengene Corporation Limited

Market Cap 165.13Cr 193.88Cr 25Cr 22Cr 20Cr 19Cr 35Cr 2.32TCr 36Cr 244.56Cr 97Cr 1.24TCr 93Cr 91Cr 3.92TCr P/E 2026 *
4.53x
P/E 2027 * -18.5x
Enterprise Value 165.13Cr 193.88Cr 25Cr 22Cr 20Cr 19Cr 35Cr 2.32TCr 36Cr 244.56Cr 97Cr 1.24TCr 93Cr 91Cr 3.92TCr EV / Sales 2026 *
1.99x
EV / Sales 2027 * 4.89x
Free-Float
62.77%
Yield 2026 *
-
Yield 2027 * -
1 day-0.71%
1 week-0.36%
Current month+0.36%
1 month-8.35%
3 months-39.59%
6 months-44.00%
Current year-26.12%
1 week 2.68
Extreme 2.68
2.98
1 month 2.62
Extreme 2.62
3.22
Current year 2.62
Extreme 2.62
6.28
1 year 2.62
Extreme 2.62
6.28
3 years 0.5
Extreme 0.5
8.16
5 years 0.5
Extreme 0.5
13.06
10 years 0.5
Extreme 0.5
22.5
Manager TitleAgeSince
Chief Executive Officer 60 28/08/2018
Chief Tech/Sci/R&D Officer 42 20/05/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 60 28/08/2018
Director/Board Member 51 09/11/2020
Director/Board Member 59 14/04/2023
Date Insider Type Main position Quantity % Market Cap. Importance
04/11/26 Other -3,472 0.0005% -
04/11/26 Other

Director

-251 0.0000%
10/09/26 Other

Director

2,00,000 0.0294%
Change 5-day change 1-year change 3-year change Capi.($)
-0.71%-0.36%-41.91%+75.00% 25Cr
+0.01%+11.10%+60.83%+70.43% 6.83TCr
+1.22%+9.56%+15.97%+90.23% 6.03TCr
+0.24%+1.35%+23.78%+97.55% 5.59TCr
+1.60%+19.44%+28.80%+112.95% 4.84TCr
-1.32%+4.78%+29.15%+40.40% 4.53TCr
-3.54%-0.60%+207.76%+879.50% 4.18TCr
-3.33%+6.90%+22.78%+48.07% 3.45TCr
-2.19%-3.71%+90.94%+66.33% 3.38TCr
-1.53%+1.12%+46.99%+0.12% 2.6TCr
Average -0.95%+5.42%+48.51%+148.06% 4TCr
Weighted average by Cap. -0.65%+5.25%+55.27%+153.56%

Financials

2026 *2027 *
Net sales 83Cr 97Cr 12Cr 11Cr 10Cr 9.33Cr 18Cr 1.17TCr 18Cr 122.97Cr 49Cr 624.23Cr 47Cr 46Cr 1.97TCr 34Cr 40Cr 5.05Cr 4.53Cr 4.18Cr 3.79Cr 7.18Cr 473.88Cr 7.38Cr 50Cr 20Cr 253.89Cr 19Cr 19Cr 802.61Cr
Net income 33Cr 39Cr 4.99Cr 4.47Cr 4.12Cr 3.74Cr 7.08Cr 467.61Cr 7.28Cr 49Cr 20Cr 250.53Cr 19Cr 18Cr 791.99Cr -8.48Cr -9.95Cr -1.27Cr -1.14Cr -1.05Cr -95.25L -1.8Cr -118.98Cr -1.85Cr -13Cr -5Cr -64Cr -4.76Cr -4.66Cr -201.51Cr
Net Debt - -
Projected Income Statement - Annual - Antengene Corporation Limited
Logo Antengene Corporation Limited
Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.
Employees
122
Date Price Change Volume
11/26/11 HK$2.800 -0.71% 2,41,000
10/26/10 HK$2.820 +4.64% 3,91,500
09/26/09 HK$2.695 -4.43% 3,82,000
06/26/06 HK$2.820 -4.41% 3,32,000
05/26/05 HK$2.950 +4.98% 5,66,500
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.402CNY
Average target price
4.150CNY
Spread / Average Target
+72.78%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Antengene Corporation Limited
  1. Stock Market
  2. Stocks
  3. 6996 Stock